Pfizer strikes out on Inlyta expansion bid by Eric Sagonowsky Wednesday, April 11, 2018 Pfizer has been looking to expand Inlyta's use to kidney cancer patients at a high risk of disease recurrence after surgery—but it's fallen short.
Roche's Tecentriq-Avastin pairing bests Sutent in kidney cancer by Tracy Staton Monday, December 11, 2017 With Tecentriq and Avastin's trial win over Sutent in first-line kidney cancer, Roche scored new points in its quest to advance the combo.
Pfizer’s Sutent approved to prevent recurrence of kidney cancer by Eric Palmer Friday, November 17, 2017 Pfizer’s old dog Sutent has shown it has one more trick to perform as a renal cancer treatment before being passed up by the new breed of I-O drugs.
Pfizer's Sutent expansion snags on tie panel vote by Tracy Staton Thursday, September 21, 2017 Pfizer is counting on a new approval for Sutent, its kidney cancer drug, but an FDA advisory panel isn’t so sure.
BMS' Opdivo-Yervoy combo slashes kidney cancer death risk by Tracy Staton Sunday, September 10, 2017 A one-two punch with Bristol-Myers' Opdivo and Yervoy cut the risk of death by 37% for kidney cancer patients with a poor prognosis.
Pfizer's Sutent comes up big in adjuvant kidney cancer trial by Carly Helfand Monday, October 10, 2016 Pfizer’s kidney-cancer fighter Sutent is an aging drug--but it may just have one more label expansion up its sleeve.
